TRDA

SEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · derivative · entry 9

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,154

Underlying: Common Stock · 2,403 shares

Expires 2030-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · nonDerivative · entry 5

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,716

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · nonDerivative · entry 4

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,119

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

SEC source: 0001689375-22-000032 · wf-form4_166439931631699.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,811

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.21 to $16.550, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000032 · wf-form4_166439931631699.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,026

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000034 · wf-form4_166439953248663.xml · nonDerivative · entry 2

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,339

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.12 to $16.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000034 · wf-form4_166439953248663.xml · nonDerivative · entry 1

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,627

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · derivative · entry 8

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,557

Underlying: Common Stock · 3,068 shares

Expires 2030-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · nonDerivative · entry 3

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,716

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.20 to $16.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · nonDerivative · entry 2

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,016

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · nonDerivative · entry 1

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,784

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

SEC source: 0001689375-22-000029 · wf-form4_166396653628463.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,355

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000031 · wf-form4_166396674271987.xml · nonDerivative · entry 2

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,422

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000030 · wf-form4_166396664564604.xml · derivative · entry 6

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,625

Underlying: Common Stock · 939 shares

Expires 2030-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001689375-22-000030 · wf-form4_166396664564604.xml · nonDerivative · entry 4

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,716

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000030 · wf-form4_166396664564604.xml · nonDerivative · entry 3

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,655

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

SEC source: 0001689375-22-000029 · wf-form4_166396653628463.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,373

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000031 · wf-form4_166396674271987.xml · nonDerivative · entry 1

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,445

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000030 · wf-form4_166396664564604.xml · derivative · entry 5

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,564

Underlying: Common Stock · 3,341 shares

Expires 2030-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001689375-22-000030 · wf-form4_166396664564604.xml · nonDerivative · entry 2

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,716

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000030 · wf-form4_166396664564604.xml · nonDerivative · entry 1

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,057

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

SEC source: 0001689375-22-000027 · wf-form4_166361963989994.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,648

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022.

SEC source: 0001689375-22-000028 · wf-form4_166361972573007.xml · nonDerivative · entry 1

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 219,847

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.01 to $15.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000026 · wf-form4_166361953637742.xml · derivative · entry 3

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,905

Underlying: Common Stock · 106 shares

Expires 2030-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001689375-22-000026 · wf-form4_166361953637742.xml · nonDerivative · entry 2

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,716

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.01 to $15.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000026 · wf-form4_166361953637742.xml · nonDerivative · entry 1

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,822

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

SEC source: 0001689375-22-000018 · wf-form4_166301365870769.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,748

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000022 · wf-form4_166301404769113.xml · nonDerivative · entry 2

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 220,047

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000020 · wf-form4_166301390290805.xml · derivative · entry 6

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,011

Underlying: Common Stock · 800 shares

Expires 2030-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001689375-22-000020 · wf-form4_166301390290805.xml · nonDerivative · entry 4

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,716

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000020 · wf-form4_166301390290805.xml · nonDerivative · entry 3

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,516

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

SEC source: 0001689375-22-000018 · wf-form4_166301365870769.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,613

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000022 · wf-form4_166301404769113.xml · nonDerivative · entry 1

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 220,735

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000020 · wf-form4_166301390290805.xml · derivative · entry 5

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,811

Underlying: Common Stock · 1,221 shares

Expires 2030-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001689375-22-000020 · wf-form4_166301390290805.xml · nonDerivative · entry 2

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,716

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000020 · wf-form4_166301390290805.xml · nonDerivative · entry 1

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,937

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.

SEC source: 0001104659-22-097873 · tm2225276-4_4seq1.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,525

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

SEC source: 0001104659-22-097876 · tm2225276-2_4seq1.xml · nonDerivative · entry 1

Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,144

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

SEC source: 0001104659-22-097878 · tm2225276-1_4seq1.xml · nonDerivative · entry 1

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,489

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

SEC source: 0001104659-22-097874 · tm2225276-3_4seq1.xml · nonDerivative · entry 1

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,716

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

SEC source: 0001104659-22-097872 · tm2225276-5_4seq1.xml · nonDerivative · entry 1

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,835

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

SEC source: 0001689375-22-000016 · wf-form4_166197928416013.xml · nonDerivative · entry 5

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,710

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

SEC source: 0001689375-22-000016 · wf-form4_166197928416013.xml · nonDerivative · entry 4

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,881

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

SEC source: 0001689375-22-000016 · wf-form4_166197928416013.xml · nonDerivative · entry 3

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,071

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

SEC source: 0001689375-22-000016 · wf-form4_166197928416013.xml · nonDerivative · entry 2

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,096

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-22-000016 · wf-form4_166197928416013.xml · nonDerivative · entry 1

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,601

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-22-095126 · tm2224609-1_4seq1.xml · nonDerivative · entry 4

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,986

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.74 to $14.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-22-095126 · tm2224609-1_4seq1.xml · derivative · entry 5

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,807

Underlying: Common Stock · 1,117 shares

Expires 2030-11-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

F5 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001104659-22-095126 · tm2224609-1_4seq1.xml · nonDerivative · entry 3

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,537

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.17 to $14.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-22-095126 · tm2224609-1_4seq1.xml · nonDerivative · entry 2

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,838

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.06 to $13.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.